No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
EXAS240719P65000
- 12.48
- 0.000.00%
15min DelayClose May 9 10:50 ET
0.00High0.00Low
0.00Open12.48Pre Close0 Volume0 Open Interest65.00Strike Price0.00Turnover129.94%IV-5.74%PremiumJul 19, 2024Expiry Date15.33Intrinsic Value100Multiplier3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9842Delta0.0079Gamma3.24Leverage Ratio-0.0192Theta-0.0028Rho-3.18Eff Leverage0.0019Vega
Intraday
- 5D
- Daily
News
Exact Sciences Corporation (EXAS) Slipped Over Investors' Concerns
These Are the Stocks With the Highest Increase in Short Interest Within Life Sciences and Diagnostics - Baird
Exact Sciences Schedules Second Quarter 2024 Earnings Call
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S.
People Are Feeling Stuck in Their Jobs. Bosses Are Starting to Worry. -- WSJ
By Chip Cutter You are likely not getting a big promotion this year. So how about a job swap? Many workers say they are considering that question as they feel stuck in their roles. With the white-co
Exact Sciences Price Target Cut to $72.00/Share From $80.00 by Evercore ISI Group
Exact Sciences Price Target Cut to $72.00/Share From $80.00 by Evercore ISI Group
Exact Sciences Is Maintained at Outperform by Evercore ISI Group
Exact Sciences Is Maintained at Outperform by Evercore ISI Group
Comments
$Exact Sciences(EXAS.US$ guys relax sooner or later this will grow just not so soon
1
1
$Exact Sciences(EXAS.US$ whats happening? why it keeps dropping?
$Exact Sciences(EXAS.US$ Good opportunity to buy after correction, "not today" I shall buy in next week once volatility minimized. Good AI stoks but you can see good return not before 2025. I am bullish on it and it will remain my best pick for next 3-5 years invetment tenure.
2
Exact Sciences' progress has failed to meet high market expectations, yet its consistent revenue growth suggests it may be worth further investigation. The company's performance has underperformed the broader market, which gained around 31%.
2
Read more
Baboompiak : yup holding onto 100 shares at 57.5